Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
BNT162b2 COVID-19 백신 수혜자의 점막 면역 반응
Clinical Trial
[키워드] acquisition
activated
Antibody titre
baseline
BNT162b2
BNT162b2 mRNA
BNT162b2 mRNA vaccine
collected
Concentration
COVID-19
COVID-19 vaccine
Department
elicit
ELISA
entry of SARS-CoV-2
first dose
generate
healthcare worker
highest
IgA
IgG
immune response
Immunity
increase
induce
magnitude
Medicine
mRNA BNT162b2
much higher
mucosal
neutralizing antibody
protocol
Quantitative
recipient
Saliva
Sample
SARS-CoV-2
second dose
seronegative
seropositive individual
seropositive individuals
seropositive subjects
serum
serum IgG
significantly
single dose
subjects
supported
surgery
systemic immune response
titre
total antibody
Umberto
university
vaccination
vaccine dose
virus
were measured
[DOI] 10.1016/j.ebiom.2021.103788 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/j.ebiom.2021.103788 PMC 바로가기 [Article Type] Clinical Trial